A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin

The Effects of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on Insulin Sensitivity in Overweight and Obese Subjects With Hypertension

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00185094

Enrollment

Registered

2005-09-16

Start date

2004-02-29

Completion date

2005-07-31

Last updated

2005-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Insulin Resistance, Metabolic Syndrome

Brief summary

To examine the effect of three different blood pressure medications on the insulin sensitivity in overweight patients with high blood pressure.

Interventions

DRUGOlmesartan medoxomil

DRUGLosartan potassium

DRUGAtenolol

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Patients between the ages of 18 and 75 years (inclusive) * Willingness to undergo insulin clamp procedure twice * Overweight or obese (BMI=25-39 kg/m2) * Subject must meet one of the following two blood pressure criteria at week-2 and at week-1: Systolic blood pressure 140-179 mmHg and diastolic blood pressure 85-99 mmHg OR Systolic blood pressure \< 140 mmHg and diastolic blood pressure 90-99 mmHg * If female, must have negative serum pregnancy test at screening and be either post-menopausal, had a hysterectomy or tubal ligation at least 6 months before consent or if of childbearing potential, must practice approved measures of birth control throughout study

Exclusion criteria

* Systolic blood pressure \> 179 mmHg * Diastolic blood pressure \> 99 mmHg or \< 85 mmHg * Diagnosis of diabetes mellitus * History of myocardial infraction, percutaneous transluminal coronary revascularization, coronary artery bypass graft, unstable angina pectoris or an episode of heart failure requiring hospitalization * Previous history of a cerebrovascular accident or a transient ischemic attack * History of allergic response to atenolol, losartan potassium, olmesartan medoxomil or any of their components * Any serious disorder, including pulmonary, hepatic, renal, gastrointestinal (including clinically significant malabsorption), uncontrolled endocrine/metabolic, hematologic/oncologic (within the last 5 years), neurologic, and psychiatric diseases, that would interfere with the conduct of the study or interpretation of the data * Laboratory abnormalities that could compromise subject safety

Design outcomes

Primary

Measure	Time frame
To compare the treatment effect of olmesartan medoxomil versus that of atenolol on insulin sensitivity	—

Secondary

Measure	Time frame
-To compare the treatment effect of losartan potassium versus atenolol on insulin sensitivity	—
-To compare the treatment effect of olmesartan medoxomil versus losartan potassium on insulin sensitivity	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026